EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.4.1.12 | Aspergillosis |
8486238 |
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
2
2
0 |
| 2.4.1.12 | Aspergillosis |
11770831 |
Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms. |
therapeutic application
unassigned |
4
0 |
| 2.4.1.12 | Aspergillosis |
29610204 |
SCY-078, a Novel Oral Glucan Synthase Inhibitor, for the Treatment of Invasive Aspergillosis: Evaluation of Antifungal Activity Singly and in Combination. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 2.4.1.12 | Candidiasis |
11770831 |
Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms. |
therapeutic application
unassigned |
4
0 |
| 2.4.1.12 | Candidiasis |
12654645 |
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. |
ongoing research
therapeutic application
unassigned |
1
3
0 |
| 2.4.1.12 | Candidiasis, Invasive |
25512406 |
Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model. |
ongoing research
therapeutic application
unassigned |
2
4
0 |
| 2.4.1.12 | Candidiasis, Invasive |
29177447 |
Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. |
therapeutic application
unassigned |
4
0 |
| 2.4.1.12 | Candidiasis, Invasive |
31871074 |
Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 2.4.1.12 | Candidiasis, Vulvovaginal |
30885896 |
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. |
therapeutic application
unassigned |
4
0 |
| 2.4.1.12 | Cysts |
23015739 |
?-1,3-glucan, which can be targeted by drugs, forms a trabecular scaffold in the oocyst walls of Toxoplasma and Eimeria. |
causal interaction
therapeutic application
unassigned |
2
1
0 |
